New drug hope for rare immune disorder? safety trial begins
NCT ID NCT04097561
First seen Jan 05, 2026 · Last updated May 21, 2026 · Updated 22 times
Summary
This early-stage study tests whether belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition where the body has too few CD4 immune cells, raising infection risk. About 20 adults aged 18-70 with ICL and autoantibodies will receive 8 doses of belimumab through an IV over several months. The main goal is to check for side effects, while also tracking changes in immune cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.